US-based biologics firm BioFactura has become the latest to join the crowd of biosimilars developers targeting Janssen’s $8bn Stelara (ustekinumab) brand, announcing the start of Phase I trials for the BFI-751 version of the inflammatory diseases treatment that is being developed by being developed by BioFactura Australia.
BioFactura Joins Stelara Biosimilar Crowd
US-Based Developer Throws Its Hat Into The Ring For Ustekinumab
Janssen’s Stelara is continuing to attract a growing crowd of proposed biosimilar rivals, with BioFactura becoming the latest to throw its hat into the ring after kicking off Phase I trials for its BFI-751 version.
